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The diastolic properties of the left ventricle are determined
by factors influencing both its passive distensibility and the
active processes of myocardial relaxation (1). At the cellular
level, these determinants include changes in the structure
and function of intramyofilament proteins such as titin,
extramyofilament proteins such as microtubules, interstitial
proteins such as fibrillar collagen, as well as the cellular and
molecular processes that control calcium homeostasis. All
these factors may influence left ventricular (LV) diastolic
stiffness, pressure, suction, and filling. In this issue of the
Journal, Selby et al. (2) investigated the cellular and molec-
ular mechanisms influencing myocardial calcium homeosta-
sis and their effects on passive and active myocardial
properties. These investigators are among the first to use
human myocardial tissue samples to examine the mecha-
nisms causing or contributing to LV diastolic dysfunction.
The authors made several observations that have important
clinical implications, particularly for patients with pressure
overload–induced LV remodeling, diastolic dysfunction,
and heart failure.
See page 147
Selby et al. (2) made measurements of myocardial con-
traction and relaxation in isolated strips of myocardium that
were obtained from LV biopsies performed in 14 patients at
the time of cardiac surgery. In one-half of the patients,
diastolic (resting) tension was increased and, when the
stimulation rate was increased from 60 to 180 beats/min,
there were further increases in diastolic tension. These
myocardial strips had evidence of incomplete relaxation at a
baseline stimulation rate of 60 beats/min; in addition,
*Editorials published in the Journal of the American College of Cardiology reflect the
views of the authors and do not necessarily represent the views of JACC or the
American College of Cardiology.
From the †Ralph H. Johnson Department of Veterans Affairs Medical Center and
the Medical University of South Carolina, Charleston, South Carolina; and the
‡Department of Cardiovascular Medicine, Lahey Clinic, Burlington, Massachusetts.
The authors have reported that they have no relationships to disclose.relaxation abnormalities became more marked at an in-
creased stimulation rate of 180 beats/min. Six of these 7
strips with incomplete relaxation were obtained from pa-
tients with echocardiographic evidence of LV hypertrophy
(LVH). In a second group of myocardial strips obtained
from patients without LVH, there was no evidence of
relaxation abnormalities (i.e., no change in diastolic tension)
at either 60 or 180 beats/min. Selby et al. (2) then evaluated
myocardial mechanical properties that reflect calcium ho-
meostasis and the cellular mechanisms that determine cel-
lular calcium transport. In the group with incomplete
relaxation and LVH, the authors found a substantial in-
crease in resting tone, abnormal diastolic actin-myosin
cross-bridge activation, and an increased cellular calcium
load during contraction and relaxation that were “due to a
reduced sarcolemmal calcium extrusion reserve” (abnormal-
ities in the sodium-calcium exchanger). These unique ob-
servations contribute to a better understanding of the
underlying mechanisms that cause LV diastolic dysfunction,
to the pathophysiological processes that lead to the devel-
opment of heart failure, and to a growing base of informa-
tion that supports the concept of distinct differences in the
pathophysiology of systolic heart failure (SHF) and diastolic
heart failure (DHF).
Mechanical Measurements and
Mechanisms of Calcium Homeostasis
The authors did not directly measure intracellular calcium
but used a series of very cleverly devised methods that are
thought to reflect changes in intracellular calcium and their
control mechanisms. The results from post-rest contraction
and rapid cooling contracture experiments reflected sarco-
plasmic reticulum (SR) calcium content, retention, release,
reuptake, and leak. The results of these experiments indi-
cated that in muscle strips with incomplete relaxation, SR
calcium content and release were increased compared with
muscle strips with normal relaxation. In addition, systolic
tension (total tension at peak contraction) in muscle strips
exhibiting incomplete relaxation was increased at both 60
and 180 beats/min. Thus, resting tension was increased in
muscle strips exhibiting incomplete relaxation, but devel-
oped tension was similar in the 2 groups.
Cross-bridge deactivation produced by treatment with
2,3-butanedione monoxime (BDM) provided the means to
quantitate increased resting tone. BDM treatment of myo-
cardial strips with incomplete relaxation decreased diastolic
tension to levels comparable to those of muscle strips with
normal relaxation. The increased diastolic tension (resting
tone) caused by persistent cross-bridge interaction was a
result of elevated cytosolic diastolic calcium. Inhibition of
SR calcium ATPase using cyclopiazonic acid and of the SR
calcium release channels by ryanodine allowed the investi-
gators to assess the contribution of sarcolemmal calcium
transport, largely a function of the sodium-calcium ex-
changer. These studies indicated that the sarcolemmal
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amounts of calcium entering the cell as the stimulation rate
is increased (reduced reserve capacity) in muscle strips with
incomplete relaxation.
Pathophysiology of
Symptom Development in Heart Failure
Data from the study of Selby et al. (2) indicated that an
increase in available cytosolic calcium during diastole caused
a persistent increase in actin-myosin cross-bridge activation
and increased diastolic tone. These cellular and molecular
changes would be expected to express themselves hemody-
namically as an increase in resting diastolic pressure that
might be expected to increase further during exercise or a
tachyarrhythmia. These cellular and molecular changes,
therefore, provide a mechanism for exercise limitation and
intolerance to tachycardia that is so common in patients
with DHF.
The authors were cautious not to directly refer to the
patients with incomplete relaxation and LVH as having
heart failure. However, the balance of their data indicates
that these patients had both the LV structural and func-
tional substrate for, if not the actual evidence of, DHF.
Indeed, exercise and its accompanying tachycardia would
likely have resulted in increased LV diastolic pressures and
symptoms of exercise intolerance in the patients with LVH
and incomplete myocardial relaxation. These patients,
whose filling pressures were mildly increased at rest, would
very likely have had an increase in diastolic pressures in an
ambulatory setting during activities of daily living. Previous
studies using implantable hemodynamic monitors demon-
strated that patients similar to those studied by Selby et al.
(2) had LV diastolic pressures at the upper limit of normal
under resting conditions (night-time minimum pressures);
however, under ambulatory conditions (24-h median pres-
sures), diastolic pressures increased significantly (3). Thus,
even modest increases in heart rate, those that occur during
daily ambulatory activities, may be sufficient to increase
diastolic pressures and cause symptoms (New York Heart
Association functional classes II to III) in patients with
LVH and incomplete relaxation. Such patients would meet
most criteria for DHF.
SHF Versus DHF
The clinical presentation of patients with DHF is virtually
the same as that seen in patients with SHF; congestion is
common to both. However, these 2 syndromes are not
components of a continuum, nor do they represent the
evolution or progression of a single disorder. Indeed, these
2 heart failure syndromes have substantially different phe-
notypes and pathophysiology. Several recent studies show
differences in epidemiology (frequency distribution and
demographic features); organ, cellular, extracellular, and
molecular structure; and function as well as responses to
pharmacological treatment (4–13).First, the distribution of LV ejection fraction in popula-
tions of patients with heart failure is bimodal (4). This is
consonant with 2 clinical syndromes; the patients with a
reduced ejection fraction (EF) exhibit features of SHF,
whereas those with a preserved EF have DHF. Moreover,
epidemiological studies have confirmed distinct differences
in the clinical characteristics of these 2 clinical syndromes.
For example, coronary atherosclerosis is significantly more
common in SHF than DHF. By contrast, older age,
female sex, and systemic arterial hypertension are more
common in DHF than in SHF. Such epidemiological
data indicate that SHF and DHF are “pathophysiologi-
cally disparate entities” (5).
Second, the hearts of patients with DHF differ dramat-
ically from those of patients with SHF with regard to both
structure and function (6–8). The hearts of those with
DHF generally exhibit concentric LV remodeling with
normal or near-normal end-diastolic volume, increased wall
thickness, and a high ratio of mass to volume. By contrast,
the hearts of patients with SHF exhibit eccentric remodel-
ing with an increase in end-diastolic volume, little increase
in wall thickness, and a substantial decrease in the ratio of
mass to volume. These dramatic differences in organ mor-
phology and geometry are paralleled by anatomic differences
at the microscopic level. In DHF, cardiomyocytes exhibit an
increased diameter, and there is an increase in the amount of
collagen with a corresponding increase in the width and
continuity of the fibrillar components of the extracellular
matrix. By contrast, in SHF, the cardiomyocytes are elon-
gated, and there are degradation and disruption of the
fibrillar collagen. These differences in LV and myocardial
structure are associated with differences in LV systolic and
diastolic function and indicate distinct differences in the
pathophysiology of SHF and DHF.
Third, studies on SHF have demonstrated significant
abnormalities in the cellular and molecular mechanisms that
control calcium homeostasis. However, the changes in
calcium homeostasis in SHF are quite different from those
found by Selby et al. (2) in patients with DHF (Fig. 1). Six
of 9 characteristics differ in SHF and DHF. In addition,
these observations reinforce findings of previous studies that
demonstrated that patients with DHF did not exhibit
discernable abnormalities in LV systolic pump performance
(6–8). In the patients studied by Selby et al. (2), LVEF was
normal and myocardial systolic function as measured by
developed tension was normal. Thus, there were distinct
differences in calcium homeostasis in SHF and DHF.
Fourth, to date, all 5 randomized clinical trials in patients
with heart failure with a preserved ejection fraction (DHF)
that used pharmacological treatments (all of which had been
previously shown to be beneficial in SHF) had a neutral
effect on cardiovascular morbidity and mortality (9–13).
This difference in response to treatment suggests that
patients with DHF are different from patients with SHF.
These studies support the need to develop different man-
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Implications for the Management of DHF
Why is avoidance of tachycardia so important in patients
with diastolic dysfunction and DHF? As heart rate in-
creases, there is an obligatory decrease in the length of
diastole, so that the tasks of relaxation, pressure decline,
recoil, and filling must occur more rapidly in a shorter
diastolic period to maintain low diastolic pressures. Because
patients with LVH and incomplete relaxation cannot aug-
ment the efficiency of diastolic function, tachycardia leads to
increased LV diastolic pressure and symptoms of heart
failure. Therefore, the data from Selby et al. suggest that
inappropriate tachycardia in patients with DHF should be
avoided. However, even with a normal or slow heart rate,
diastolic dysfunction persists. Even with a very long diastolic
period, increased diastolic tone prevents a decrease in LV
diastolic pressure to normal. Therefore, although prevention
of excessive tachycardia is a cardinal component of treat-
ment, heart rates less than physiological are not likely to be
of therapeutic value. In addition, because agents such as
beta-adrenergic blockers and calcium channel blockers have
negative effects on diastolic function, careful titration of
doses must be made. The tendency for beta-adrenergic
Figure 1 Cellular and Molecular Differences
Between SHF and DHF
Differences in cellular and molecular processes that influence myocardial cal-
cium homeostasis in patients with systolic heart failure (SHF) and those with
diastolic heart failure (DHF). The arrows indicate increased (*), decreased (+),
and no difference (N) compared with normal controls. Open arrows represent
circumstances in which there are differences between SHF and DHF. [Ca2] 
cytosolic calcium concentration; Na/Ca  sodium/calcium; SR  sarcoplasmic
reticulum.blockers to promote chronotropic incompetence should alsobe considered, especially in older patients. Clearly, future
therapeutic trial design should take into account the differ-
ences in SHF and DHF discussed here.
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